Aegea Biotechnologies, Inc. Expands its Platforms for COVID-19 Testing under the Collaboration Agreement with TAUG
April 20 2020 - 8:51AM
InvestorsHub NewsWire
Aegea
Biotechnologies, Inc. Expands its Platforms for Novel Coronavirus
(COVID-19) Testing under the Collaboration Agreement with Tauriga
Sciences, Inc.
NEW YORK, NY and SAN DIEGO, CA -- April 20, 2020 -- InvestorsHub
NewsWire -- As previously announced, Tauriga Sciences, Inc.
(TAUG)
(“Tauriga”) and Aegea Biotechnologies, Inc. (“Aegea”) have entered
into a collaboration agreement to develop COVID-19 (Novel
Coronavirus) assays. Aegea has now informed Tauriga Sciences that
in addition to the high sensitivity, high specificity COVID-19
assay under development (the “SARS-CoV-2 Test”), Aegea is
undertaking to use another of its patented technologies to further
expand COVID-19 testing to very simple devices appropriate to
point-of-care testing. The patent being applied is core to a
follow-on assay designed to use isothermal amplification as covered
by US Patent 10,174,352 for METHODS FOR AMPLIFICATION OF NUCLEIC
ACIDS ON SOLID SUPPORT. This methodology combines the capture of
nucleic acid targets of interest, together with isothermal
amplification on solid surfaces. Due to the fact that this method
works at a single uniform temperature, it can be used with very
simple devices applicable to point-of-care and point-of-testing.
This includes simplistic lateral flow devices. Additionally, it
works directly with RNA targets, like that used in COVID-19
testing, in that the genome of coronavirus is a single stranded
RNA.
“We are pleased to make available another of Aegea’s patented
technologies in the testing for COVID-19. This methodology can
assist in more global testing for this virus as the current
pandemic continues or as it recurs. It can also be used for future
epidemics or pandemics when they occur,” said Lyle Arnold Ph.D.,
CEO and Founder for Aegea Biotechnologies. Dr. Arnold continued,
“To further accelerate the development of this simplified assay,
Aegea is in discussion with external resources, including
foundations and federal agencies.”
Dr. Arnold is an inventor or co-inventor on 54 issued US patents
and more than 200 issued and pending patents world-wide, which in
aggregate have been core to products that have generated billions
of dollars in revenue. Dr. Arnold is a co-inventor of the
isothermal solid phase technology described here.
Tauriga’s CEO, Mr. Seth Shaw, states, “The breadth of Aegea’s
intellectual property portfolio enables us to address COVID-19
testing in multiple important ways. We are pleased to be
collaborating with Aegea and can confirm that Tauriga has already
contributed its first tranche of capital (pursuant to April 3rd
Agreement). The Company plans to increase its contributions to help
expedite the commercialization of these important technologies that
have the potential to help the global community.”
ABOUT TAURIGA SCIENCES, INC.
Tauriga Sciences, Inc. (TAUG)
is a revenue generating, diversified life sciences company, engaged
in several major business activities and initiatives. The
company manufactures and distributes several proprietary retail
products and product lines, mainly focused on the Cannabidiol
(“CBD”) and Cannabigerol (“CBG”) Edibles market segment. The
Company’s commercialization strategy consists of a broad array of
retail customers, distributors, and a fast-growing E-Commerce
business segment (E-Commerce website: www.taurigum.com). Please
visit our corporate website, for additional information, as well as
inquiries, at www.tauriga.com
Complimentary to the Company’s retail business, are its two
ongoing biotechnology initiatives. The first one relates to the
development of a Pharmaceutical grade version of Tauri-Gum™, for
nausea regulation (specifically designed to help patients that are
subjected to ongoing chemotherapy treatment). On March 18,
2020, the Company announced that it filed a provisional U.S. patent
application covering its pharmaceutical grade version of
Tauri-Gum™. The Patent, filed with the U.S.P.T.O. is Titled
“MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS
OF TREATMENT”. The second one relates to a collaboration agreement
with Aegea Biotechnologies Inc. for the co-development of a rapid,
multiplexed, Novel Coronavirus (COVID-19) test with superior
sensitivity and selectivity.
The Company is headquartered in New York City and operates a
regional office in Barcelona, Spain. In addition, the Company
operates a full-time E-Commerce fulfillment center located in
LaGrangeville, New York.
CONTACT INFORMATION:
Tauriga Sciences, Inc.
555 Madison Avenue, 5th Floor
New York, NY 10022
Chief Executive Officer
Mr. Seth M. Shaw
Email: sshaw@tauriga.com
cell # (917) 796 9926
Instagram:
@tauri_gum
Twitter: @SethMShaw
Corp. Website: www.tauriga.com
E-Commerce
Website: www.taurigum.com
Tauriga Sciences (CE) (USOTC:TAUG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tauriga Sciences (CE) (USOTC:TAUG)
Historical Stock Chart
From Apr 2023 to Apr 2024